- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05360680
A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers
Study Overview
Status
Intervention / Treatment
Detailed Description
CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies by selective engagement and expansion of tumor antigen-specific T cells that should allow for increased potential for anti-cancer efficacy and reduced toxicity relative to non-targeted forms of immunotherapy that result in systemic activation of the immune system.
The goal of Part A is to characterize the safety, tolerability, and biological effects of CUE-102.
The goal of Part B is to expand the safety and immune activity data at the RP2D identified in Part A, and to evaluate antitumor activity at this dose.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Steven Margossian, M.D., Ph.D.
- Phone Number: 857-228-0636
- Email: smargossian@cuebio.com
Study Contact Backup
- Name: Reena Lynam
- Phone Number: 617-949-2637
- Email: rlynam@cuebio.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85054
- Recruiting
- Mayo Clinic
-
Contact:
- Bekaii Saab
-
Principal Investigator:
- Bekaii Saab
-
-
California
-
Los Angeles, California, United States, 90048
- Recruiting
- Cedars-Sinai Medical Center
-
Contact:
- Katherine Eckert
- Phone Number: 310-967-2781
- Email: katherine.eckert@cshs.org
-
Palo Alto, California, United States, 94304
- Not yet recruiting
- Stanford Advanced Medicine Cancer Center
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Contact:
- Lauren Ponto
- Phone Number: 813-745-7658
- Email: lauren.ponto@moffitt.org
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Winship Cancer Institute
-
Contact:
- Katie Coleman
- Phone Number: 404-251-1278
- Email: kathleen.marie.coleman@emory.edu
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Recruiting
- Johns Hopkins University
-
Contact:
- Lei Zheng, M.D, PhD
- Phone Number: 410-502-6241
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic - Rochester
-
Principal Investigator:
- Zhaohui Jin
-
Contact:
- Preston Buechler
- Phone Number: 507-422-5917
- Email: buechler.preston@mayo.edu
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Recruiting
- Carol G. Simon Cancer Center - Morristown Medical Center
-
Principal Investigator:
- Christopher Chen
-
Contact:
- Amanda Hall
- Email: AmandaMaria.Hall@atlantichealth.org
-
-
New York
-
Bronx, New York, United States, 10461
- Recruiting
- Montefiore Medical Center
-
Contact:
- Gunnar Lauer
- Phone Number: 718-405-8124
- Email: glauer@montefiore.org
-
-
North Carolina
-
Huntersville, North Carolina, United States, 28078
- Recruiting
- Carolina BioOncology Institute
-
Contact:
- Ashley Wallace
- Email: awallace@carolinabiooncology.org
-
Principal Investigator:
- John Powderly, M.D.
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Recruiting
- Gabrail Cancer Center
-
Principal Investigator:
- Nashat Gabrail, M.D.
-
Contact:
- Carrie Smith
- Phone Number: 330-417-8231
- Email: csmith@gabrailcancercenter.com
-
Cleveland, Ohio, United States, 44106
- Recruiting
- Cleveland Medical Center (University Hospitals)
-
Contact:
- UH SCC Cancer Information Services
- Phone Number: 800-641-2422
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson Cancer Center
-
Contact:
- Jing Peng
- Phone Number: 713-792-2208
- Email: jingpeng@mdanderson.org
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Recruiting
- Northwest Medical Specialties, PLLC
-
Contact:
- Sue Quinsey
- Phone Number: 253-428-8700
- Email: squinsey@nwmsonline.com
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- Carbone Cancer Center
-
Contact:
- Cancer Connect
- Phone Number: 608-262-5223
-
Contact:
- Phone Number: 1-800-622-8922
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease.
- Age ≥18 years old
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy ≥12 weeks
- Measurable disease as per RECIST 1.1 and documented by CT and/or MRI.
- All tumors must have histologically or cytologically confirmed cancer diagnosis
Patients must have any of the following cancers to be eligible:
A. Colorectal cancer
- Histologically or cytologically documented adenocarcinoma of colon or rectum at the time of initial presentation
- Metastatic or locally advanced/unresectable disease
- Documented disease progression after the last administration of standard therapies or intolerance to at least 2 prior systemic treatment regimens (CUE-102 will be 3rd line therapy or greater).
B. Gastric cancer (including gastroesophageal junction)
- Histologically or cytologically documented gastric cancer at the time of initial presentation
- Metastatic or locally advanced/unresectable disease
- Documented disease progression after last administration of standard therapies or intolerance to standard therapies. (CUE-102 will be 2nd line therapy or greater).
C. Pancreatic cancer
- Histologically or cytologically documented pancreatic adenocarcinoma at the time of initial presentation
- Patients with metastatic or locally advanced/unresectable disease.
- Prior systemic treatment must include either a fluoropyrimidine-based or gemcitabine-based regimen in either the (neo)adjuvant or relapsed setting. (CUE-102 will be 2nd line therapy or greater).
D. Ovarian cancer
- Histologically or cytologically documented ovarian cancer at the time of initial presentation
- Metastatic or locally advanced/unresectable disease, with documented disease progression after last administration of standard therapies or intolerance to standard therapies.
- Prior systemic treatment must include a platinum-based regimen. (CUE-102 will be 2nd line therapy or greater).
- For patients determined to have platinum-sensitive disease, treatment with a second platinum-based combination regimen +/- bevacizumab should be considered prior to treatment with CUE-102 (CUE-102 will be 3rd line therapy or greater).
- Patient must have HLA-A*0201 genotype as determined by genomic testing.
- Patient must have histologically and/or cytologically proven tumor(s) that is WT1 positive.
- Acceptable laboratory parameters.
- Female patients of childbearing potential must agree to use acceptable contraceptive measures from the time of main study consent through 90 days after discontinuation of study drug administration.
- Non-vasectomized male patients with partners of childbearing potential must use barrier contraception from the time of main study consent through 90 days after discontinuation of study drug.
- Patients who have previously received an immune CPI (e.g., anti-programmed cell death ligand 1 (anti PD-L1), anti-programmed cell death 1 (anti-PD-1), anti-cytotoxic T lymphocyte-associated antigen 4 [CTLA-4]) prior to enrollment must have toxicities related to the CPI resolved to CTCAE ≤ Grade 1 or baseline (level prior to the CPI) to be eligible for enrollment. Patients who have experienced CPI-related endocrinopathies (e.g., diabetes, adrenal insufficiency) may participate if endocrinopathies are controlled (CTCAE ≤ Grade 1) with endocrinology support and appropriate repletion. Note: Patients who experienced previous hypothyroidism toxicity on a CPI are eligible to enter study regardless of CTCAE grade resolution as long as the patient is well controlled on thyroid replacement hormone.
Exclusion Criteria:
- Female patients who are pregnant or plan to become pregnant during the course of the trial
- Female patients who are breastfeeding
Patients with symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic, and not have any of the following at the time of enrollment:
- Need for concurrent treatment for the CNS disease (e.g., surgery, radiation, corticosteroids >10 mg prednisone/day or equivalent)
- Progression of CNS metastases on CT or MRI for at least 28 days after last day of prior therapy for the CNS metastases
- Concurrent leptomeningeal disease or cord compression.
- Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.
- History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation
- Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 14 days (or 28 days, for antibody drugs), before the first dose of CUE-102.
- Treatment with radiation therapy within 14 days before the first dose of CUE-102
- Treatment with corticosteroids (> 10 mg per day prednisone or equivalent) or other immune suppressive drugs within 14 days before the first dose of CUE-102. Steroids for topical, ophthalmic, inhaled, or nasal administration are permitted. Physiological replacement with up to a maximum dose of 5 mg equivalence of prednisone per day is permitted.
- History of clinically significant cardiovascular disease
- Clinically significant pulmonary compromise (e.g., requirement for supplemental oxygen)
- Clinically significant gastrointestinal (GI) disorders
Patients who experienced the following immune CPI-related AEs are ineligible even if the AE resolved to ≤ Grade 1 or baseline:
- ≥ Grade 3 ocular AE
- Changes in liver function tests that met the criteria for Hy's Law (> 3× ULN of either ALT/AST with concurrent > 2× ULN of total bilirubin (total and direct) and without alternate etiology)
- ≥ Grade 3 neurologic toxicity
- ≥ Grade 3 colitis
- ≥ Grade 3 renal toxicity
- Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days before the first dose of CUE-102.
- No known history of infection or positive test for HIV, Hepatitis B or Hepatitis C, testing prior to enrollment is not required unless mandated by local authority
- Second primary invasive malignancy that has not been in remission for > 2 years.
- History of trauma or major surgery within 28 days before the first dose of CUE-102
- Any serious underlying medical or psychiatric condition that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site
- Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for CUE-102
- Vaccination with any live virus vaccine within 28 days before the first dose of CUE-102. Inactivated annual influenza vaccination is allowed.
- Dementia or altered mental status that would preclude understanding and rendering of informed consent
- Active or history of significant alcohol or other substance abuse within 1 year before the first dose of CUE-102
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CUE-102 (1mg/kg) Dose Escalation
CUE-102 (1 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
|
CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
|
Experimental: CUE-102 (2 mg/kg) Dose Escalation
CUE-102 (2 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
|
CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
|
Experimental: CUE-102 (4 mg/kg) Dose Escalation
CUE-102 (4 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
|
CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
|
Experimental: CUE-102 (8 mg/kg) Dose Escalation
CUE-102 (8 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
|
CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
|
Experimental: CUE-102 Dose Expansion at Determined RP2D
Dose expansion of CUE-102 at determined RP2D Monotherapy IV infusion every 3 weeks for up to 2 years
|
CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Limiting Toxicity
Time Frame: 21 Days
|
Evaluate dose-limiting toxicities (DLTs) during the first cycle of treatment with CUE-102, and to establish a recommended Phase 2 dose (RP2D)
|
21 Days
|
Maximum Tolerated Dose
Time Frame: 21 Days
|
Evaluate maximum tolerated dose (MTD) to establish a recommended Phase 2 dose (RP2D)
|
21 Days
|
Serum PK AUC for CUE-102
Time Frame: Up to 2 years
|
Area under the concentration-time curve (AUC) of CUE-102.
|
Up to 2 years
|
Serum PK Cmax for CUE-102
Time Frame: Up to 2 years
|
Maximum serum concentration (Cmax) of CUE-102.
|
Up to 2 years
|
Serum PK T1/2 for CUE-102
Time Frame: Up to 2 years
|
Terminal half-life (T1/2) of CUE-102.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of CUE-102 Assessed by NCI CTCAE v5.0
Time Frame: Up to 2 years
|
To evaluate safety and tolerability of CUE-102 using NCI CTCAE v5.0.
|
Up to 2 years
|
Antitumor Response Rate with Treatment of CUE-102
Time Frame: Up to 2 years
|
To evaluate antitumor response rate of CUE-102 by RECIST 1.1
|
Up to 2 years
|
Antitumor Duration of Response with Treatment of CUE-102
Time Frame: Up to 2 years
|
To evaluate antitumor duration of response of CUE-102 by RECIST 1.1
|
Up to 2 years
|
Antitumor Clinical Benefit Rate with Treatment of CUE-102
Time Frame: Up to 2 years
|
To evaluate antitumor clinical benefit rate of CUE-102 by RECIST 1.1
|
Up to 2 years
|
Progression-Free Survival with Treatment of CUE-102
Time Frame: Up to 2 years
|
To evaluate antitumor progression-free survival of CUE-102 by RECIST 1.1
|
Up to 2 years
|
Overall Survival with Treatment of CUE-102
Time Frame: From First CUE-102 to Date of Death
|
To evaluate overall survival after treatment with CUE-102
|
From First CUE-102 to Date of Death
|
Immune Response Assessed by WW1 Tetramer-Positive T cell Lymphocytes
Time Frame: Up to 2 years
|
To evaluate the potential for immune response after treatment with CUE-102 using assessment of number of WT1 tetramer-positive T cell lymphocytes.
|
Up to 2 years
|
Immune Response Assessed by CTL Markers of Activation
Time Frame: Up to 2 years
|
To evaluate the potential for immune response after treatment with CUE-102 using assessment of cytotoxic T lymphocyte (CTL) markers of activation
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Matteo Levisetti, MD, Cue Biopharma
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CUE-102-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on CUE-102
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)Completed
-
University of California, San DiegoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Completed
-
Indiana UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Recruiting
-
Boston University Charles River CampusRecruiting
-
Brigham and Women's HospitalNational Institute on Aging (NIA)CompletedRheumatic Diseases | Lupus Erythematosus, Systemic | Adherence, Medication | GoutUnited States
-
University of SalfordUniversity of Nottingham; University of Birmingham; Stroke Research Network; University...Completed
-
Marco LeytonActive, not recruitingTobacco Use | Addiction Nicotine | Cigarette SmokingCanada
-
The University of Hong KongCompleted
-
Wayne State UniversityNational Institute on Drug Abuse (NIDA)CompletedMarijuana AbuseUnited States
-
University of LeedsRecruiting